2
Polpharma Strengthens Its Position in Central and Eastern Europe – Biofarm, the Leader of the Romanian Market, Joins the Group
more
Stories about Pharmaindustrie
Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich
Aachen, Germany (ots) - Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic ...
moreGrünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy
Aachen (ots) - Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). Tegacorat, a non-steroidal Selective Glucocorticoid ...
moreGrünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist
Aachen (ots) - - The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. - In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. - A Phase II trial will commence later this year. Grünenthal announced today that the ...
moreDER AKTIONÄR publisher Bernd Förtsch calls for transparency in BioNTech founders’ spin-off - legal action under review
Kulmbach, Germany (ots) - Bernd Förtsch, founder and CEO of Börsenmedien AG, has submitted an extensive catalogue of questions to BioNTech. At the centre of the matter is the spin-off of significant assets to a new company owned by departing founders Dr Ugur Sahin and Dr Özlem Türeci, announced on March 10th ...
morePromising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
Tübingen (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed Phase 2a PROHEAR Study. ACOU085 is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across ...
more
LTS Lohmann Therapie-Systeme AG
LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions
Andernach (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company specializing in advanced drug delivery systems, today announced the expansion of its service portfolio to include CDMO services for ophthalmic drug delivery solutions, with manufacturing capacities located in the United States at LTS’ Lakewood, New Jersey facility. The new offering focuses initially on product ...
moreLAUDA DR. R. WOBSER GMBH & CO. KG
4Temperature Control Specialist Honors Global Sales Achievements
more- 2
Press Release: STADA’s Strong Growth Journey Continues in 2025
One documentmore Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm
Aachen, Germany & Yeoju, South Korea (ots) - Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will ...
moreGrünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands
Aachen, Germany (ots) - - Grünenthal acquired Kyowa Kirin International's 49% stake in 'Grünenthal Meds', a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. - Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 ...
moreGrünenthal licenses exclusive Australian rights to Qutenza® to Clinect
Aachen, Germany & Victoria, Australia (ots) - Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a ...
more
- 5
PM: DHL Group stärkt Logistik für das weltweite Gesundheitswesen durch Ausbau des Kühlkettennetzwerks in der Luftfracht / PR: DHL Group Expands Airfreight Cold Chain Network to Advance Global Health Logistics
2 Documentsmore Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development
Aachen, Germany (ots) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in ...
morePress Release: STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi
STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi - European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA ...
One documentmore- 2
Investment of 80 million Euros.
more Grünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex
Aachen, Germany & Toronto, Canada (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to ...
moreServier delivers solid performance in 2024/25 and confirms its forecasts for 2030
Suresnes, France (ots/PRNewswire) - - Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. - Growth over the financial year was driven by increased sales in oncology, particularly in the United States. - Several partnership agreements in oncology and neurology strengthen the Group's R&D portfolio in rare diseases. - Achieving 2025 ...
more
Press release: STADA’s Head of Communications Frank Staud additionally leads Global Government Affairs
One documentmoreAcousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small ...
morePress Release: Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion - Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marketed by STADA - ...
One documentmoreXlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity
morePress Release: STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe
STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
3 DocumentsmorePress Release: STADA Sponsors PingPongParkinson World Championship in Italy
One documentmore
LTS Lohmann Therapie-Systeme AG
LTS expands its CDMO capabilities with the acquisition of Renaissance Lakewood
Andernach (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company today announces the acquisition of Renaissance Lakewood, LLC (“Renaissance”), a US-based contract development and manufacturing organization (CDMO) specializing in nasal sprays and sterile dosage forms. With the acquisition, Renaissance facilities will become ...
moreLetter of Intent for strategic partnership / Vaccentis and TrueMed join forces to advance cancer vaccine
Zurich (ots) - Vaccentis, a Zurich based biotech company specializing in the development of therapeutic protein-based tumor vaccines, has signed a letter of intent with TrueMed, a leading commercialization partner. Accelerating cancer vaccine against renal cell carcinoma The aim of this letter of intent is to ...
moreKerry Establishes New Biotechnology Centre in Leipzig / Centre to facilitate cutting-edge innovations with wide range of applications across food, beverage and pharma
Leipzig (ots) - Kerry, a global leader in taste and nutrition, has today inaugurated the Kerry Biotechnology Centre in Leipzig, Germany, which will focus on the development of innovative biotech solutions across food, beverage, and pharma applications. New capabilities in biotechnology are opening the field to ...
moreEuropäischer Rechnungshof - European Court of Auditors
Läkemedelsbristen är fortfarande en kronisk huvudvärk för EU
moreEuropäischer Rechnungshof - European Court of Auditors
Lääkepula yhä EU:n päänsärkynä
moreEuropäischer Rechnungshof - European Court of Auditors
Medicinmangler er en hovedpine for EU
more
123456Next